Key facts
- It has raised $50.0M; the latest was Capitalization ($50.0M) in Jan 2025.
- Status: Privately Held (no backing).
- ·Watchlist + deal alerts for Quetzal Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Quetzal Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Quetzal Therapeutics
Developer of biopharmaceutical treatments designed for the treatment of rare diseases including hematologic malignancies. The company researches and develops therapies for Acute Promyelocytic Leukemia, an antifungal and antiparasitic candidate in pre-clinical development, conducts clinical trials to evaluate product candidates
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2025
- Employees
- 14
- Website
- quetzaltx.com/
- Ownership
- Privately Held (no backing)
Quetzal Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Quetzal Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Quetzal Therapeutics in its N-PORT filings yet. We sweep new filings monthly.